Felipe Duran, the Chief Financial Officer of $IBIO, bought 24,835 shares of the company on 03-19-2026 for an estimated $50,131. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 223.0%. Following this trade, they now own 35,974 shares of this class of $IBIO stock.
$IBIO Insider Trading Activity
$IBIO insiders have traded $IBIO stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IBIO stock by insiders over the last 6 months:
- FELIPE DURAN (Chief Financial Officer) purchased 24,835 shares for an estimated $50,131
- MARTIN BRENNER (See Remarks) purchased 12,336 shares for an estimated $24,918
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IBIO Hedge Fund Activity
We have seen 37 institutional investors add shares of $IBIO stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 2,228,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,300,040
- AFFINITY ASSET ADVISORS, LLC added 2,057,200 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,970,396
- LOGOS GLOBAL MANAGEMENT LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,860,000
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. added 1,953,467 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,770,191
- BALYASNY ASSET MANAGEMENT L.P. added 1,085,779 shares (+10440.2%) to their portfolio in Q4 2025, for an estimated $2,095,553
- LYNX1 CAPITAL MANAGEMENT LP removed 1,055,897 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,037,881
- SIO CAPITAL MANAGEMENT, LLC added 740,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,428,200
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IBIO Analyst Ratings
Wall Street analysts have issued reports on $IBIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 10/21/2025
- Leerink Partners issued a "Outperform" rating on 10/17/2025
To track analyst ratings and price targets for $IBIO, check out Quiver Quantitative's $IBIO forecast page.
$IBIO Price Targets
Multiple analysts have issued price targets for $IBIO recently. We have seen 4 analysts offer price targets for $IBIO in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Keay Nakae from Chardan Capital set a target price of $5.0 on 03/18/2026
- Catherine Novack from Jones Trading set a target price of $7.0 on 03/03/2026
- Jay Olson from Oppenheimer set a target price of $5.0 on 10/21/2025
- Roanna Ruiz from Leerink Partners set a target price of $2.0 on 10/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
